Shuvayu Sen is a seasoned pharmaceutical executive with deep expertise in real-world evidence, market access, health economics, and outcomes research. As Vice President and Head of Oncology within Merck’s Center for Observational & Real-World Evidence (CORE), he brings a unique blend of academic rigor and strategic business leadership to advancing access to oncology innovations globally. Dr. Sen holds a Ph.D. in Pharmaceutical Economics and Outcomes Research from Purdue University and serves as an Adjunct Professor at Rutgers University. With extensive leadership experience across major pharmaceutical companies, he has led global efforts in pricing, reimbursement, big data analytics, policy research, and health technology assessment (HTA) for pharmaceuticals, vaccines, and digital health technologies. His work spans multiple therapeutic areas including oncology, neuroscience, infectious disease, immunology, and women’s health. Recognized for his ability to generate novel insights and impactful evidence strategies, Dr. Sen has consistently driven access and formulary success in the U.S., EU, and emerging markets. He is known for building effective partnerships across for-profit and non-profit sectors and for his collaborative leadership style that inspires cross-functional teams.

At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals.